Report Summary

The Global Immuno Oncology Market Size was estimated at USD 12,008.1 Million in 2019 and is expected to grow at a CAGR of 21.8% for the forecast period from 2020-2025. Immuno-oncology, also known as cancer immunotherapy is a biologic treatment, which boosts the body's natural defenses to stop the growth of cancer. This therapy uses constituents made by the body or in a research laboratory to improve or reestablish the immune system function. Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Currently, world is at the forefront of this science with several compounds in development that are being investigated for use in a variety of cancers, as well as an approved immuno-oncology medicine that continues to be studied for new uses. The more precise targeting of patients for selected therapies is another important area of focus in oncology. Clinical biomarkers and pharmacogenomic studies are increasingly used to identify groups and sub-groups of patients most likely to benefit from an investigational agent in order to maximize its potential benefits.

The global immuno oncology market growth is majorly driven by the number of deaths arising owing to cancer is increasing every year and this has consequently enforced government organizations to take initiatives for the development of the health environments of individuals, by investing in R&D and enabling innovation with technological advancement so as to offer improved treatments. In addition, healthcare providers are concentrating on refining cancer therapies and decrease reappearance of cancer post-chemotherapy. This has pushed the growth of the immuno-oncology market globally.



Know more about this report: request for sample pages

The Immuno-Oncology market highlights started when the anti-CTLA-4 therapy i.e. Yervoy was launched by BMS IN 2013 but the most notable growth was observed when two of the therapies i.e. Pembrolizumab (Keytruda) by Merck and Nivolumab (Opdivo) by BMS targeting anti PD-1 therapies were launched for the treatment of melanoma cancer at the end of 2014. The rapid growth of these therapies and successful clinical results in several other oncology therapy areas has fuelled the overall growth of Immuno-Oncology market.

The increasing trend was also seen in the research in the novel agents and increase in the number of clinical trials in combinations as well as monotherapy. The most notable new agents in Immuno-Oncology are IDO’s, LAG-3, TIGIT, TIM-3, VISTA, KIR, NKG2A, B7-H3/H4. The immuno oncology market report has also emphasized on the Oncolytic viruses, Neo-Antigen therapies, TCR Therapies and CAR-T therapies.

Immuno Oncology Market Scope

The global immuno-oncology market is segmented on the basis of treatment approaches, Novel Targets, by tumor type and region.

By Treatment Approaches By Novel Targets By Tumor Types By Region Monoclonal Antibodies

Therapeutic Vaccines

Checkpoint Inhibitors

Cytokines IDO1i

LAG-3 CPI

Oncolytic virus

STING agonist

TLR agonist

HDACi

TIL

VEGFi

MEKi

TIGIT

CPI

GITR agonist

TGF-b trap

A2AR antagonist/CD73i Melanoma

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Head & Neck Cancer

Bladder Cancer

Classical Hodgkin’s Lymphoma

Merkel Cell Carcinoma

Others North America (U.S., Canada, Mexico)

Europe (Germany, UK)

Asia-Pacific (China, Japan, India)

Latin America (Brazil)

Middle East and Africa

Know more about this report: request for sample pages

Segment Analysis

On the basis of treatment type, the global immuno-oncology market is segmented into Monoclonal Antibodies, Therapeutic Vaccines, Checkpoint Inhibitors, and Cytokines. Checkpoint inhibitors were the largest treatment process segment in 2019 that accounted for 55.2% of the overall revenue. On the basis of novel targets, the global market is segmented into IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, and A2AR antagonist/CD73i. VEGFi was the largest novel target segment that was used for immuno-oncology treatment processes in 2019 with a total market share of 11.2%. on the basis of tumor type, the global immuno-oncology Market is segmented into Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Head, face & Neck Cancer, Bladder Cancer, Classical Hodgkin’s Lymphoma, Merkel Cell, and carcinoma. Revenue share of immuno-oncology treatment for classical hodgkin’s lymphoma was the largest in 2017 i.e. 15.31% among the listed tumor types in the report.

Immuno Oncology Therapies

Polaris Market expects that the Immuno Oncology therapies continues to be the improved and personalized treatment options for the cancer patients.

The major segments which has been investigated in the global market from 2015-2025 are

Market Analysis by Marketed Immuno-Oncology Therapies

Market Analysis by Cancer Type

Market Analysis by Novel Targets

The Marketed Therapies undertaken in forecast from 2015-2025 are

Yervoy (Bristol Myers Squibb)

Keytruda (Merck)

Opdivo (Bristol Myers Squibb)

Tecentriq (Roche)

Bavencio (Merck/Pfizer)

Imfinzi (AstraZeneca)

Epacadostat (Incyte Pharmaceuticals)

Tremelimumab (AstraZeneca)

The Major Indications in Immuno-Oncology Therapies are

Melanoma

Lung Cancer

Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC)

Head & Neck Squamous Cell Carcinoma (HNSCC)

Renal Cell Cancer

Bladder Cancer

Leading Companies investigated in the Report are

Bristol Myers Squibb

Merck

AstraZeneca

Roche

Pfizer

Incyte

Regional Analysis

North America was the largest regional market in 2019 with a market share of 30.4%. The regional market is expected to grow over the forecast period and account for 31.6% in 2025. Cancer patient count in the U.S. is among the top countries in the world. Moreover, the country has some of the world leading cancer institutions that constantly carry out technological developments in very frequent intervals. Development of immuno-oncology has been the works of some of the leading institutes in the region specifically the U.S. In addition, growing availability of drugs for this treatment process in the region along with the ability to afford such treatment cost of the people and presence of all the novel technological innovations with the equipment required are some of the major factors driving the regional market.